

<遠隔基準>

- ・放射線治療開始(2003-2005)
- ・遠隔
- ・遠隔転移
- ・傍大動脈リンパ節への転移
- ・先行または同時発生の重複癌症例
- ・放射線治療歴
- ・患者分類

<患者情報>

- ・施設名
- ・施設カルテ番号 ※匿名化
- ・氏名漢字 ※匿名化
- ・氏名カナ(全角) ※匿名化
- ・性別 ※匿名化
- ・生年月日(YYYY/MM/DD) ※匿名化
- ・診断時郵便番号 ※匿名化
- ・診断時住所(都道府県名) ※匿名化
- ・診断時住所(市町村以下) ※匿名化
- ・本籍郵便番号 ※匿名化
- ・本籍住所(都道府県名) ※匿名化
- ・本籍住所(市町村以下) ※匿名化

<病歴>

- ・高血圧
- ・不整脈
- ・虚血性心疾患
- ・糖尿病
- ・肝炎
- ・肝硬変
- ・脳梗塞 or 一過性脳虚血
- ・KPS

<検査データ>

- ・治療前PSA
- ・診断時PSA(日時)(YYYY/MM/DD)
- ・診断時PSA(値)(ng/ml)
- ・放射線治療開始前PSA(日時)(YYYY/MM/DD)
- ・放射線治療開始前PSA(値)(ng/ml)
- ・画像評価
- ・CT
- ・MRI
- ・骨シンチ

<病理組織>

- ・生検
- ・病理確定日(YYYY/MM/DD)
- ・診断方法
- ・陽性本数
- ・生検本数
- ・病理診断結果
- ・Gleason primary
- ・Gleason secondary
- ・Gleason score
- ・分化度

<病期>

- ・TNM分類
- ・TStage
- ・NStage
- ・ABCD分類
- ・日本泌尿器科学会病期分類

<手術1>

- ・手術
- ・前立腺全摘除術
- ・手術日(YYYY/MM/DD)
- ・手術手技
- ・神経血管束温存
- ・手術結果
- ・前立腺摘出断端

・精囊浸潤

- ・術後照射を行う理由
- ・尿失禁の有無

<手術2>

- ・病理学的浸潤
- ・int
- ・INF
- ・ur
- ・ly
- ・cap
- ・b
- ・v
- ・sv
- ・r
- ・pn
- ・Gleason score
- ・Pathological
- ・内臓骨リンパ節(411)
- ・外臓骨リンパ節(403)
- ・閉鎖リンパ節(410)
- ・総臓骨リンパ節(413)
- ・坐骨リンパ節(412)
- ・傍大動脈リンパ節(325)
- ・鼠径リンパ節(401)
- ・切除断端部癌浸潤
- ・近位側断端PW
- ・遠位側断端DW
- ・転移リンパ節数
- ・切除リンパ節数

<放射線治療1>

- ・臨床試験
- ・試験No
- ・放射線治療を選んだ理由
- ・外照射
- ・小線源治療
- ・入院の有無

<放射線治療2>

- ・内分泌療法施行
- ・開始日(YYYY/MM/DD)
- ・最終追跡日まで継続しているか?
- ・終了日(YYYY/MM/DD)
- ・内分泌療法併用時期
- ・RT前内分泌療法施行
- ・RT中内分泌療法施行
- ・RT後ホルモン療法施行
- ・内分泌療法内容
- ・除癌術
- ・エストロゲン剤
- ・LHRH
- ・抗アンドロゲン剤
- ・その他の内分泌療法
- ・化学療法施行
- ・開始日(YYYY/MM/DD)
- ・終了日(YYYY/MM/DD)
- ・薬剤1~5
- ・その他の治療

<治療計画>

- ・CT治療計画装置を使用したか?
- ・治療計画用CTの種類
- ・治療計画にMRI画像を参照したか?
- ・X線シミュレータを使用したか?
- ・尿道、直腸に対する造影剤の使用
- ・治療体位
- ・固定具
- ・照射確認のためのポータルフィルムやEPIDの使用

<外部照射1>

- ・外照射開始日(YYYY/MM/DD)
- ・外照射終了日(YYYY/MM/DD)
- ・1日で全門照射
- ・照射装置
- ・原体照射/IMRT
- ・ブロック/MLC
- ・CTV
- ・根治/ホルモン不応外照射
- ・術後
- ・外照射_小線源併用

<外部照射2>

- ・全骨盤照射 照射法
- ・全骨盤照射 X線エネルギー
- ・全骨盤照射 照射野X x Y(cm) 1~3
- ・全骨盤照射 1回の照射線量(cGy)
- ・全骨盤照射 総線量(cGy)
- ・全骨盤照射 線量評価点
- ・全骨盤照射 具体的に記載
- ・全骨盤照射 CTVの定義
- ・小骨盤照射 照射法
- ・小骨盤照射 X線エネルギー
- ・小骨盤照射 照射野X x Y(cm) 1~3
- ・小骨盤照射 1回の照射線量(cGy)
- ・小骨盤照射 総線量(cGy)
- ・小骨盤照射 線量評価点
- ・小骨盤照射 具体的に記載
- ・小骨盤照射 CTVの定義
- ・局所#1~3 照射法
- ・局所#1~3 X線エネルギー
- ・局所#1~3 照射野X x Y(cm) 1~3
- ・局所#1~3 1回の照射線量(cGy)
- ・局所#1~3 総線量(cGy)
- ・局所#1~3 線量評価点
- ・局所#1~3 具体的に記載
- ・局所#1~3 CTVの定義
- ・外照射線量(cGy)

<小線源治療1>

- ・放射性同位元素の種類
- ・線量率
- ・処方線量(Gy)
- ・麻酔方法
- ・アプローチ
- ・テンプレート使用
- ・X線イメージ使用
- ・TRUS使用
- ・PTV
- ・線源配置法
- ・術前計画用の画像
- ・針刺入ガイド用の画像
- ・術前前立腺体積推定(ml)
- ・針刺入本数(本)
- ・マージン(mm)

<小線源治療2>

- ・高線量率 1回線量(cGy)
- ・高線量率 分割回数
- ・高線量率 分割間隔
- ・高線量率 治療開始日(YYYY/MM/DD)
- ・高線量率 治療終了日(YYYY/MM/DD)
- ・高線量率 治療日数
- ・低線量率 線源強度(MBq)
- ・低線量率 線源本数(本)
- ・低線量率 総放射能(MBq)
- ・低線量率 刺入日
- ・低線量率 治療計画時期
- ・低線量率 移動線源有無
- ・低線量率 移動線源個数
- ・低線量率 移動線源部位

・計画年月日

- ・術後計画の画像
- ・PTV V100(%)
- ・PTV V150(%)
- ・PTV D90(Gy)
- ・直腸 V100(ml)
- ・直腸 V150(ml)
- ・尿管 V200(ml)
- ・尿管 D90(Gy)
- ・尿管 D5(Gy)

<経過>

- ・生死/転帰
- ・最終経過観察日(YYYY/MM/DD)
- ・死亡日(YYYY/MM/DD)
- ・死因
- ・他疾患による病死の場合、疾患名

<再発>

- ・臨床的再発は起こったか?
- ・再発部位
- ・再発日(YYYY/MM/DD)
- ・PSA再発は起こったか?
- ・PSA再発日(YYYY/MM/DD)
- ・再発時PSA値(ng/mL)
- ・PSA再発の定義
- ・Salvage治療内容

<急性有害事象>

- ・急性有害事象は生じたか?
- ・消化管 下痢グレード
- ・消化管 直腸炎グレード
- ・泌尿生殖器 頻尿グレード
- ・泌尿生殖器 尿道狭窄グレード

<晩期性有害事象>

- ・晩期有害事象は生じたか?
- ・消化管 消化管閉塞発生日(YYYY/MM/DD)
- ・消化管 消化管閉塞グレード
- ・消化管 直腸炎発生日(YYYY/MM/DD)
- ・消化管 直腸炎グレード
- ・消化管 直腸出血発生日(YYYY/MM/DD)
- ・消化管 直腸出血グレード
- ・泌尿生殖器 血尿発生日(YYYY/MM/DD)
- ・泌尿生殖器 血尿グレード
- ・泌尿生殖器 尿失禁発生日(YYYY/MM/DD)
- ・泌尿生殖器 尿失禁グレード
- ・泌尿生殖器 尿道狭窄発生日(YYYY/MM/DD)
- ・泌尿生殖器 尿道狭窄グレード
- ・放射線治療前ED
- ・放射線治療後ED

——>>>Menu

Database
Surveyor
Current number
help

——>>>Eligibility

ID
NO
Date Input
Institution
Chart ID Hospital
Case Initial
Chart ID RT department
Treated from 1999 to 2002
Female Male
Invasive Non invasive
Gross multicentric disease
Diffuse calcification on mammogram
Distant metastasis
Bilateral lesion
Prior concurrent malignancies
Prior history of RT for breast
Collagen vascular disease except RA
Case Eligible

——>>>Demogra

Zip code
Date of birth
RT Department Medical Record
Other Department Outpatient Medical Record
Other Department Inpatient Medical Record
Imaging

——>>>History

Clinical size of total lesion(cm)(Longest)
Clinical size of total lesion(cm)(Shortest)
Distance from nipple(cm)
Tumor marker CEA ng ml
Height(cm)
Weight(kg)
Grav
Para
Age of the first delivery
Menopausal status
Location of primary
Site of breast tumor
Mammography performed
Clinical T(UICC'97)1
Clinical T(UICC'97)2
Clinical N(UICC'97)
History of oral contraceptive
History of estrogen replacement therapy after menopause
Family history of breast cancer
Family history of ovarian cancer
MRI done
US done
CT done
Did MRI change treatment option?
Tumor marker

——>>>Surgery

Date of final breast surgery
Number of reexcision
Planned Other adjuvant RX

Type of final breast surgery
Final gross margin
Final microscopic margin
Residual disease on reexcision
Skin incision for BCT

——>>>Tumor path

Date of initial histological dx
Size of total lesion(cm)(Longest)
Size of total lesion(cm)(Shortest)
Size of invasive component(cm)(Longest)
Size of invasive component(cm)(Shortest)
Path report on chart
Grade
Intraductal Ca quantified
EIC
T stage(UICC'97)1
T stage(UICC'97)2
Histology1

——>>>Senti in

Sentinel lymph node biopsy
Was sentinel lymph node biopsy followed by axillary
Sentinel lymph node mapping
Was patient scanned
Where localized
Was a biopsy done of internal mammary nodes
Results of biopsy
Further axillary resection done
Date

——>>>Node path

Date of axillary surgery
of nodes positive
of nodes in axillary specimen
Node level I involved
Node level II involved
Node level III involved(Infraclavicular LN)
Intrapectoral(Rotter)
Parasternal
Supraclavicular
Retromandibular
Extracapsular extension
N staging(UICC'97)1
N staging(UICC'97)2
N staging(UICC'97)3

——>>>Receptors

Estrogen receptors
Progesterone receptors
Flow cytometry
Her2 New test

——>>>Course

Clinical trial group
Clinical trial number
Reason
Investigational protocol
Planned External beam breast
Planned External beam breast boost
Planned Brachytherapy breast
Planned Anitiestrogen
Planned Chemotherapy
Planned Autologus bone marrow transplantation
Sequence with chemoRx(Sequentially)(Aldemix)

Planned and given treatment differ
 Admission for initial treatment
 Given External beam breast
 Given External beam breast boost
 Given Brachytherapy breast
 Given Anitiestrogen
 Given Chemotherapy
 Given Autologus bone marrow transplantation
 Given Other adjuvant RX
 Planned Chest wall Breast
 Planned Supraclavicular LN
 Planned Internal mammary LN
 Given Chest wall Breast
 Given Supraclavicular LN
 Given Internal mammary LN
 Planned Axillary LN
 Given Axillary LN
 Date of admission
 Date of discharge

----->>>Chemo
 Start date
 Start date MM DD YY mild chemotherapy
 Therapy given Concurrent
 Therapy given Pre RT
 Therapy given Post RT
 Therapy given Unknown chemotherapy
 agents1 concurrent
 agents1 Pre RT
 agents1 Post RT
 agents1 unknown chemotherapy
 agents2 concurrent
 agents2 Pre RT
 agents2 Post RT
 agents2 unknown chemotherapy
 agents3 concurrent
 agents3 Pre RT
 agents3 Post RT
 agents3 unknown chemotherapy
 Therapy given small dose
 agents1 Small dose
 agents2 Small dose
 agents3 Small dose

----->>>Hormone
 Start of date Tamoxifen
 Was it given Tamoxifen
 With RT Tamo
 Post RT Tamo
 Sequence with chemoRx(Sequentially)(Tamo)
 Sequence with chemoRx(Concurrently)(Tamo)
 Sequence with chemoRx(Without chemoRx)(Tamo)
 Start of date MPA
 Start of date Aldemix
 Was it given(Medroxypro)
 With RT(Medro)
 Post RT(Medro)
 Was it given(Aldemix)
 With RT(Aldemix)
 Post RT Aldemix
 Sequence with chemoRx(Sequentially)(Medro)
 Sequence with chemoRx(Concurrently)(Medro)
 Sequence with chemoRx(Without chemoRx)(Medro)
 Use of bolus
 Boost to area of primary

Sequence with chemoRx(Concurrently)(Aldemix)
 Sequence with chemoRx(Without chemoRx)(Aldemix)
 Start of date LH RH
 Was it given(LHRH)
 With RT(LHRH)
 Post RT(LHRH)
 Sequence with chemoRx(Sequentially)(LHRH)
 Sequence with chemoRx(Concurrently)(LHRH)
 Sequence with chemoRx(Without chemoRx)(LHRH)

----->>>Rx plan
 Reference point(Isodose for Interstitial)
 Maximum lung thickness irradiated on simulator film(cm)
 Cast was used
 Shell was used
 Simulation
 Isodose curves based on
 Isodose for external beam
 Reference point
 Isodose for interstitial
 Field description documented
 Field margin Upper
 Field margin Lower
 Matching of dorsal margin of RT fields

----->>>Ext beam
 Breast RT field size X
 Breast RT field size Y
 Breast(Total dose)
 Boost RT field size X
 Boost RT field size Y
 Boost(Total Dose)
 Supraclav RT field size X
 Supraclav RT field size Y
 Supraclav(Total Dose)
 Int Mam RT field size X
 Int Mam RT field size Y
 Int Mam(Total dose)
 Post Ax RT field size X
 Post Ax RT field size Y
 Post Ax(Total dose)
 Breast Beam type
 Boost Beam type
 Supraclav Beam type
 Int Mam Beam type
 Post Ax Beam type
 Breast(Energy)
 Boost(Energy)
 Supraclav(Energy)
 Int Mam(Energy)
 Post Ax(Energy)
 If whole breast RT

----->>>Fields 1
 Total breast/chest wall dose(cGy)
 Breast/chest wall fraction size(cGy)
 Isodose line specified
 Separation between tangents
 How target volume was determined
 Treatment direction to
 # of tangents treated/day
 MLC used
 Tangents wedges or compensators
 Year after Agent2 4
 Year after Agent3 4

Source of implant

——>>>Calendar

Start date1
Start date2
Start date3
Start date4
Start date6
Stop date1
Stop date2
Stop date3
Stop date4
Stop date6
Interruption1
Interruption2
Interruption3
Interruption4
Interruption6
Field change1
Field change2
Field change3
Field change4
Field change6
Irradiate1
Irradiate2
Irradiate3
Irradiate4
Irradiate6

——>>>Outcome

Last visit Date
Last contact Date
Date of death
If patient died of intercurrent disease specify
Last visit patient status
Last contact Patient status
Cause of death
Agent1
Agent3
Agent2
Year after Agent1 1
Year after Agent2 1
Year after Agent3 1
Year after Tamoxifen1
Year after MPA1
Year after LHRHag1
Year after Aldemix1
Year after Agent1 2
Year after Agent2 2
Year after Agent3 2
Year after Tamoxifen2
Year after MPA2
Year after LHRHag2
Year after Aldemix2
Year after Agent1 3
Year after Agent2 3
Year after Agent3 3
Year after Tamoxifen3
Year after MPA3
Year after LHRHag3
Year after Aldemix3
Year after Agent1 4
(1 years)Score method
first years Score by
first years Satisfaction by patient

Year after Tamoxifen4
Year after MPA4
Year after LHRHag4
Year after Aldemix4
Year after Agent1 5
Year after Agent2 5
Year after Agent3 5
Year after Tamoxifen5
Year after LHRHag5
Year after MPA5
Year after Aldemix5
Diagnostic date MM DD YY 2
Specify
Secondary primary

——>>>Manage

(Surgery)Wide excision
(Surgery)Modified radical mastectomy
(Surgery)Simple mastectomy
(Surgery)Axillary dissection
Surgery Other surgery
(Radiotherapy)Breast
(Radiotherapy)Chest wall
(Radiotherapy)Regional nodes
(Radiotherapy)Distant mets
Radiotherapy Other radiotherapy
Systemic hormones
Systemic chemotherapy

——>>>Relapse

Date of 1st recurrence
Date of 2nd recurrence
Date of 3rd recurrence
Diagnostic date MM DD YY
Recurrence
Location of 1st recurrence
Histologically proven1
Location of 2nd recurrence
Histologically proven2
Location of 3rd recurrence
Histologically proven3
Oposite breast cancer

——>>>Comp

Did patient experience any complications?
Comp1 Date
Comp2 Date
Comp3 Date
Comp4 Date
Comp1 Complication
Comp2 Complication
Comp3 Complication
Comp4 Complication
Comp1 Grade
Comp2 Grade
Comp4 Grade
Comp3 Grade

——>>>Cosmetic

Late skin change Y after RT
Breast fibrosis Y after RT
Breast atrophy Y after RT

(5 years)Score method
fifth years Score by
fifth years Satisfaction by patient
Late skin change
Breast fibrosis
Breast atrophy
Late skin change(EORTC/Joint Center Grade)
Breast fibrosis(EORTC/Joint Center Grade)
Breast atrophy(EORTC/Joint Center Grade)
Skin reaction acute year
Skin reaction late year
Late reaction of soft tissue year
Skin reaction acute
Skin reaction late
Late reaction of soft tissue
Skin reaction acute grade
Skin reaction late grade
Late reaction of soft tissue grade

----->>>Comment

Comments

——>>>Menu

Surveyor
Total number in database
Current number
help

——>>>Eligibility

ID
NO
Date Input
Institution
Chart ID Hospital
Case Initial
Treated from 1999 to 2001
Distant metastasis
Prior concurrent malignancy
Carcinoma
Prior pelvic RT
Chart ID RT department
Case Eligible

——>>>Demographics

Date of birth
Zip code
RT Department Medical Record
Other Department Outpatient Medical Record
Other Department Inpatient Medical Record
Imaging diagnosis
Treatment option
Imaging treatment

——>>>History

Pulmonary disease
Cardiovascular disease
Diabetes
Inflammatory bowel disease
Collagen vascular disease
HIV positive
History of PID
STD
Liver disease
HCV
History Other
Height cm
Weight(Kg)
Grav
Para
Number of previous major abdominopelvic surgery
Karnofsky

——>>>Labs

Transfusion/60days prior
Transfusion during RT
Tumor marker CEA(ng/ml)
Tumor marker SCC(ng/ml)
Total protein
Within normal range CEA
Within normal range SCC
Lowest preRX hemoglobin surgery

——>>>Pathology

Path report on chart
Histology
Differentiation JSOG2ndEd
Treatment goal

Differentiation USA PCS'9699

Conization
Vessel permeation
Date of conization MM DD YY
Depth of invasion mm
Extent of longitudinaldirection mm

——>>>Staging

Ltmed parametrium
Ltpelvic wall
Rtmed parametrium
Rtpelvic wall
Hydronephrosis/Nonfunctioning
Rectum
Bladder
Other structure
Restaging FIGO3
Restaging FIGO2
Restaging FIGO1
Staging system
Lower 1/3 vagina
Middle 1/3 vagina
Upper 1/3 vagina
Other structure specify
Stage

——>>>Imaging

Cystoscope
Protoscope
Barium enema
IP
Chest X p
Pelvic CT
abdominal CT
MRI
Bone scan
US
Tumor evaluation
Tumor evaluation method
Maximum diameter
LN evaluation
LN evaluation method
Did imaging change staging
LAG
PET
FNA
lapalotomy
Enlarged pelvic node
Enlarged paraaortic node

——>>>Rxplan

Treatment plan stated
Investigational protocol
Planned Ext beam
Planned Intracavitary
Planned Interstitial
Planned Hysterectomy
Planned ChemoRx
Planned Other
Given Other
Given ChemoRx
Given Hysterectomy
Given Intracavitary
Given Ext beam
Fractions2

Patient completed planned treatment
 Reason incomplete
 Reason of failure of brachytherapy
 Treatment given differs from plan
 Hospitalization
 Protocol group
 Given Interstitial
 Protocol number

——>>>Exb1

Any ext beam Rx done elsewhere
 Simulation done
 Prescription point
 Reason3 for break s
 Unplanned breaks in RT
 Reason2 for break s
 Reason1 for break s
 Midline block
 Daily fraction size(cGy)
 Pelvic field upper border2
 Pelvic field upper border1
 Shaped field
 Where
 Start of RT
 End of central pelvic RT
 End of ext beam RT
 Field size(cm) Y
 Field size(cm) X
 Isocenter depth(cm)
 %Isodose line
 If hyperfractionation was used specify1
 If hyperfractionation was used specify2
 All fields treated a day
 MLC used
 Upper margin of midline block

——>>>Exb2

Treatment position
 Region1
 Region2
 Region3
 Region4
 Region5
 Region6
 technique6
 technique4
 technique3
 technique2
 technique1
 Beam1
 Beam2
 Beam3
 Beam4
 technique5
 Beam5
 Beam6
 Dose1 cGy
 Dose3 cGy
 Dose4 cGy
 Dose5 cGy
 Dose6 cGy
 Dose2 cGy
 Fractions1
 Brachytherapy done at other facility
 Treatment planning system of brachytherapy

Fractions3
 Fractions4
 Fractions5
 Fractions6

——>>>Brachyl

Implant type1
 Implant type2
 Implant type3
 Implant type4
 Applicator type1
 Applicator type2
 Applicator type3
 Applicator type4
 Radionuclide1
 Radionuclide2
 Radionuclide4
 Radionuclide3
 Remort afterloading1
 Remort afterloading2
 Remort afterloading3
 Remort afterloading4
 vaginal applicator1
 vaginal applicator2
 vaginal applicator3
 vaginal applicator4
 Were orthogonal xray taken1
 Were orthogonal xray taken2
 Were orthogonal xray taken3
 Were orthogonal xray taken4
 Each HDR fraction planned1
 Each HDR fraction planned3
 Each HDR fraction planned2
 Each HDR fraction planned4
 Sedation1
 Sedation2
 Sedation3
 Sedation4
 Dose rate1
 Dose rate2
 Dose rate3
 Dose rate4
 Facility name
 Barachytherapy date1
 Barachytherapy date2
 Barachytherapy date3
 Barachytherapy date4
 Implant duration/hrs1(min in HDR)
 Implant duration/hrs2(min in HDR)
 Implant duration/hrs3(min in HDR)
 Implant duration/hrs4(min in HDR)
 Rectal dose ICRU1
 Rectal dose ICRU2
 Rectal dose ICRU3
 Rectal dose ICRU4
 Rectal dose in vivo1
 Rectal dose in vivo2
 Rectal dose in vivo3
 Rectal dose in vivo4
 Pt A dose cGy 1 R
 Pt A dose cGy 2 R
 Pt A dose cGy 3 R
 Pt A dose cGy 4 R
 Implant duration/hrs8(min in HDR)
 Pt A dose cGy 5 R

In vivo dosimetry rectum
 In vivo dosimetry bladder
 Reference calculation rectum
 Reference calculation bladder
 Pt A dose cGy 1 L
 Pt A dose cGy 2 L
 Pt A dose cGy 3 L
 Pt A dose cGy 4 L
 Bladder dose in vivo1
 Bladder dose in vivo2
 Bladder dose in vivo3
 Bladder dose in vivo4
 Bladder dose cGy 1
 Bladder dose cGy 2
 Bladder dose cGy 3
 Bladder dose cGy 4
 HDR implant

 ----->>>Brachy2
 Implant type5
 Implant type6
 Implant type7
 Implant type8
 Applicator type5
 Applicator type6
 Applicator type7
 Applicator type8
 Radionuclide5
 Radionuclide6
 Radionuclide7
 Radionuclide8
 Remort afterloading5
 Remort afterloading6
 Remort afterloading7
 Remort afterloading8
 vaginal applicator5
 vaginal applicator6
 vaginal applicator7
 vaginal applicator8
 Were orthogonal xray taken5
 Were orthogonal xray taken6
 Were orthogonal xray taken7
 Were orthogonal xray taken8
 Each HDR fraction planned5
 Each HDR fraction planned6
 Each HDR fraction planned7
 Each HDR fraction planned8
 Sedation5
 Sedation6
 Sedation7
 Sedation8
 Dose rate5
 Dose rate6
 Dose rate7
 Dose rate8
 Barachytherapy date5
 Barachytherapy date6
 Barachytherapy date7
 Barachytherapy date8
 Implant duration/hrs5(min in HDR)
 Implant duration/hrs6(min in HDR)
 Implant duration/hrs7(min in HDR)
 P F No of resected lymph nodes
 P F Surgical T stage2
 Facility name

Pt A dose cGy 6 R
 Pt A dose cGy 7 R
 Pt A dose cGy 8 R
 Rectal dose ICRU5
 Rectal dose ICRU6
 Rectal dose ICRU7
 Rectal dose ICRU8
 Rectal dose in vivo5
 Rectal dose in vivo6
 Rectal dose in vivo7
 Rectal dose in vivo8
 Pt A dose cGy 5 L
 Pt A dose cGy 6 L
 Pt A dose cGy 7 L
 Pt A dose cGy 8 L
 Bladder dose ICRU5
 Bladder dose ICRU6
 Bladder dose ICRU7
 Bladder dose ICRU8
 Bladder dose in vivo5
 Bladder dose in vivo6
 Bladder dose in vivo7
 Bladder dose in vivo8

 ----->>>Surgery
 Type of surgery
 Date of surgery
 S F Surgical margin Myometrium
 S F Surgical margin Parametrium
 S F Surgical margin Vaginal stump
 S F Surgical N stage
 S F Surgical T stage3
 S F Surgical T stage2
 Depth of stromal invasion
 P F Surgical T stage1
 P F Surgical T stage3
 P F Surgical margin Vaginal stump
 P F Surgical N stage
 P F Surgical margin Myometrium
 P F Surgical margin Parametrium
 Lymphvascular space invasion V
 Lymphvascular space invasion ly
 P F Sites of metastatic lymph nodes PA
 P F Sites of metastatic lymph nodes Ext iliac
 P F Sites of metastatic lymph nodes Sacral
 P F Sites of metasitatic lymph nodes Obtur
 P F Sites of metastatic lymph nodes Common iliac
 P F Sites of metastatic lymph nodes Int iliac
 P F Sites of metastatic lymph nodes Card lig
 S F Sites of metastatic lymph nodes Card lig
 S F Sites of metastatic lymph nodes Int iliac
 S F Sites of metasitatic lymph nodes Obtur
 S F Sites of metastatic lymph nodes Sacral
 S F Sites of metastatic lymph nodes Ext iliac
 S F Sites of metastatic lymph nodes Common iliac
 S F Sites of metastatic lymph nodes PA
 S F Surgical T stage1
 Tumor size longest diameter cm
 Tumor size shortest diameter cm
 SF No of surgically metastatic lymph node
 SF No of resected lymph nodes
 P F No of pathologically metastatic lymph node
 End date chemotherapy mild chemo
 Concurrent therapy given s
 Concurrent route s

Surgery done
 Surgical findings

 ——>>>Chemo
 Concurrent therapy given n
 Pre RT therapy given
 Pre RT therapy given
 Pre OP therapy given
 Unknown therapy given n
 PostOP therapy given
 Concurrent route n
 Pre RT route
 Post RT route
 Pre OP route
 Post OP route
 Unknown route n
 Concurrent agents1 n
 Pre RT agents1
 Post RT agents1
 Pre OP agents1
 Post OP agents1
 Unknown agents1 n
 Concurrent agents2 n
 Pre RT agents2
 Pre OP agents2
 Post RT agents2
 Post OP agents2
 Unknown agents2 n
 Concurrent agents3 n
 Pre RT agents3
 Pre OP agents3
 Post RT agents3
 Post OP agents3
 Unknown agents3 n
 Concurrent agents4 n
 Pre RT agents4
 Post RT agents4
 Pre OP agents4
 Post OP agents4
 Unknown agents4 n
 Concurrent agents5 n
 Pre RT agents5
 Post RT agents5
 Pre OP agents5
 Post OP agents5
 Unknown agents5 n
 Concurrent agents6 n
 Pre RT agents6
 Post RT agents6
 Pre OP agents6
 Post OP agents6
 Unknown agents6 n
 Start date chemotherapy intensive chemo
 End date chemotherapy intensive chemo
 Unknown no of cycle n
 Post OP no of cycle
 Pre OP no of cycle
 Post RT no of cycle
 Pre RT no of cycle
 Concurrent no of cycle n
 Start date chemotherapy mild chemo
 ——>>>Relapse
 Did patient relapse?
 Relapse1 Site of relapse
 Relapse2 Site of relapse

 Concurrent agents1 s
 Concurrent agents2 s
 Concurrent agents3 s
 Concurrent agents4 s
 Concurrent agents5 s
 Concurrent agents6 s
 Concurrent no of cycle s
 Small doses agents1
 Small doses agents2
 Small doses agents3
 Small doses agents4
 Small doses agents5
 Small doses agents6
 Unknown therapy given s
 Unknown route s
 Unknown agents1 s
 Unknown agents2 s
 Unknown agents3 s
 Unknown agents4 s
 Unknown agents6 s
 Unknown agents5 s
 Unknown no of cycle s

 ——>>>Doses
 Paraortic LN area External Beam
 Bladder dose ICRU External Beam
 Bladder dose invivo External Beam
 Rectal dose ICRU External Beam
 Rectal dose invivo External Beam
 Pelvic wall Lt External Beam
 Pelvic wall Rt External Beam
 Point A Left External Beam
 Point A Right External Beam
 Point A Right Brachytherapy
 Point A Left Brachytherapy
 Pelvic wall Rt Brachytherapy
 Pelvic wall Lt Brachytherapy
 Rectal dose invivo Brachytherapy
 Rectal dose ICRU Brachytherapy
 Bladder dose ICRU Brachytherapy
 Bladder dose invivo Brachytherapy
 Point A Right Total dose
 Point A Left Total dose
 Pelvic wall Rt Total dose
 Pelvic wall Lt Total dose
 Rectal dose invivo Total dose
 Rectal dose ICRU Total dose
 Bladder dose invivo Total dose
 Bladder dose ICRU Total dose
 Paraortic LN area Total dose

 ——>>>Outcome
 Last contact Patient status
 Last visit Patient status
 Karnofsky status (outcome)
 Cause of death
 Last visit Date
 Last contact Date
 Date of death
 If cause of death was 2 4 5 or 6 specify
 How was contact made?
 Comp8 Pelvic tumor(Acute)
 Comp1 Date Acute
 Comp2 Date Acute
 Comp3 Date Acute

Relapse3 Site of relapse
 Relapse4 Site of relapse
 Relapse5 Site of relapse
 Relapse1 Biopsy done
 Relapse2 Biopsy done
 Relapse3 Biopsy done
 Relapse4 Biopsy done
 Relapse5 Biopsy done
 Relapse1 Date of relapse
 Relapse2 Date of relapse
 Relapse3 Date of relapse
 Relapse4 Date of relapse
 Relapse5 Date of relapse
 Main1
 Main2
 Main3
 Main4
 Main5

——>>>Complication1

Did patient experience acute complications?

Comp1 GU Acute
 Comp2 GU Acute
 Comp3 GU Acute
 Comp4 GU Acute
 Comp5 GU Acute
 Comp6 GU Acute
 Comp7 GU Acute
 Comp8 GU Acute
 Comp1 GI Acute
 Comp2 GI Acute
 Comp3 GI Acute
 Comp4 GI Acute
 Comp5 GI Acute
 Comp6 GI Acute
 Comp7 GI Acute
 Comp8 GI Acute
 Comp1 Mis Acute
 Comp2 Mis Acute
 Comp3 Mis Acute
 Comp4 Mis Acute
 Comp5 Mis Acute
 Comp6 Mis Acute
 Comp7 Mis Acute
 Comp8 Mis Acute
 Comp1 Grade(Acute)
 Comp2 Grade(Acute)
 Comp3 Grade(Acute)
 Comp4 Grade(Acute)
 Comp5 Grade(Acute)
 Comp6 Grade(Acute)
 Comp7 Grade(Acute)
 Comp8 Grade(Acute)
 Comp1 Pelvic tumor(Acute)
 Comp2 Pelvic tumor(Acute)
 Comp3 Pelvic tumor(Acute)
 Comp4 Pelvic tumor(Acute)
 Comp5 Pelvic tumor(Acute)
 Comp6 Pelvic tumor(Acute)
 Comp7 Pelvic tumor(Acute)

Comp4 Date Acute
 Comp5 Date Acute
 Comp6 Date Acute
 Comp7 Date Acute
 Comp8 Date Acute

——>>>Complication2

Did patient experience late complications?

Comp1 GU Late
 Comp2 GU Late
 Comp3 GU Late
 Comp4 GU Late
 Comp5 GU Late
 Comp6 GU Late
 Comp7 GU Late
 Comp8 GU Late
 Comp1 GI Late
 Comp2 GI Late
 Comp3 GI Late
 Comp4 GI Late
 Comp5 GI Late
 Comp6 GI Late
 Comp7 GI Late
 Comp8 GI Late
 Comp1 Mis Late
 Comp2 Mis Late
 Comp3 Mis Late
 Comp4 Mis Late
 Comp5 Mis Late
 Comp6 Mis Late
 Comp7 Mis Late
 Comp8 Mis Late
 Comp1 Grade(Late)
 Comp2 Grade(Late)
 Comp3 Grade(Late)
 Comp4 Grade(Late)
 Comp5 Grade(Late)
 Comp6 Grade(Late)
 Comp7 Grade(Late)
 Comp8 Grade(Late)
 Comp1 Pelvic tumor(Late)
 Comp2 Pelvic tumor(Late)
 Comp3 Pelvic tumor(Late)
 Comp4 Pelvic tumor(Late)
 Comp5 Pelvic tumor(Late)
 Comp6 Pelvic tumor(Late)
 Comp7 Pelvic tumor(Late)
 Comp8 Pelvic tumor(Late)
 Comp1 Date Late
 Comp2 Date Late
 Comp3 Date Late
 Comp4 Date Late
 Comp5 Date Late
 Comp6 Date Late
 Comp7 Date Late
 Comp8 Date Late

——>>>Comment

Comments

——>>>Menu

Surveyor
Total number in database
record
help

——>>>Eligibility

ID
NO
Date input
Institution
ChartID Hospital
Case Initial
Treated from 1999 to 2001
Distant metastasis
Squamous cell adenosquamous adenocarcinoma
Stage
Tumor in thoracic esophagus only
Karnofsky greter than 50
Prior malignancies past 5 years
ChartID RT department
Case Eligible

——>>>Demographics

Gender
Date of birth
Zip code
RT Department Medical
Other Department Outpatient Medical
Other Department Inpatient Medical
Imaging

——>>>History

Pulmonary disease
Diabetes
Chronic nephritis renal failure
Karnofsky
Detected by Screening
Height cm
Body weight loss kg
Weight kg
Smoking Brinkman index pieces
Smoking Brinkman index years
Alcohol index daily
Alcohol index years
Cerebrovascular_disease
Swallowing function
Recurrent laryngeal nerve
Hypertension
Ischemic Heart Disease
Other Cardiovascular Disease
HBV HCV
Chronic Hepatitis
Cirrhosis
Cirrhosis with Varix

——>>>Workup

Multiple non dyed area by Lugol
Esophagogram circumferential
Endoscopy circumferential
Endoscopic depth and JESG 9thEd
Esophagogram
Endoscopy
N stage JESG 9th Ed by CT MRI
Planned Chemotherapy

Endoscopic US

CT of chest
Mediastinal MRI
CT of abdomen
Tumor marker CEA ng ml
Tumor marker SCC ng ml
Tumor marker CYFRA ng ml
Creatinine clearance nl min
Esophagogram length cm
Endoscopy length cm
CT length cm
CT width cm
Tumor size maximum diameter cm
Esophagogram multiple lesion
Endoscopy multiple lesion
Endoscopic US tumor invasion
Endoscopic US regional nodes
CT of chest regional nodes
CT of abdomen regional nodes

——>>>Extent

TE fistula
Pleural effusion
Regional nodes on CXR
Regional nodes on surgical exploration
Stage summary AJCC T
Stage summary UIJJ T
Stage summary JESG T
Stage summary AJCC N
Stage summary AJCC Stage
Stage summary UIJJ N
Stage summary UIJJ Stage
Stage summary JESG Stage
Stage summary JESG N
Location of tumor main
Location of tumor sub site Ce
Location of tumor sub site Ut
Location of tumor sub site Mt
Location of tumor sub site Lt
Location of tumor sub site Ae
Location of tumor sub site EGJ
If T4 specify Pericardium
If T4 specify Aorta
If T4 specify Vena cava
If T4 specify Trachea
If T4 specify Main bronchus
If T4 specify Lung
If T4 specify Diaphragm
T4 by lymph nodes
Stage summary UIJJ M
Stage summary JESG M
Stage summary AJCC M

——>>>Pathology

Histology
Differentiation
Grade

——>>>Rxcourse

Planned External beam
Given External beam
Planned Brachytherapy
Planned EMR
Planned Surgical resection
Treatment position

Planned Stent used
 Planned Gastrostomy
 Planned preOp RT
 Planned postOp RT
 Planned ioOp RT
 Given EMR
 Given Brachytherapy
 Given Surgical resection
 Given Chemotherapy
 Given Stent used
 Given Gastrostomy
 Given preop RT
 Given postop RT
 Given IORT
 Investigational protocol
 Did patient complete planned treatment
 Admission for initial treatment
 Protocol
 Intention to treat
 If other specify
 Clinical trial group

——>>>Exb1

Prescription
 If isodose line specify
 Beam type
 Beam energy
 Start date ext beam
 Simulation
 Clipping of primary lesion by endoscopy
 Stop date ext beam
 Planned split course
 Given split course
 Planned Total dose cGy
 Planned Dose/fx cGy
 Planned Total fractions
 Planned Treatment time days
 Planned If hyperfraction was used specify each1
 Planned If hyperfraction was used2
 Planned If hyperfraction was used3
 Planned Interval of each fraction hrs
 Given Dose fx cGy
 Given Total dose cGy
 Given Total fractions
 Given Treatment time days
 Given If hyperfraction was used1
 Given If hyperfraction was used2
 Given if hyperfraction was used3
 Given Interval of each fraction hrs
 Reason incomplete
 Did patient receive whole mediastinal RT
 Did patient receive supraclavicular RT
 Did patient receive upper abdominal RT
 Spinal dose cGy
 Dose of whole mediastinal RT cGy
 Dose of supraclavicular RT cGy
 Dose of upper abdominal RT cGy

——>>>Exb2

All fields treated each day
 If postoperative RT RT field includes tumor bed
 If postoperative RT RT field includes regional LNs area
 Fields reduced during RT
 Date2 HDR
 Date3 HDR

Technique AP PA
 Technique 3 fields
 Technique Arc rotation
 Technique Oblique
 Technique Other
 Dose AP PA
 Dose 3 fields
 Dose Arc rotation
 Dose Oblique
 Dose Other
 Initial RT fields size X
 Initial RT fields size Y
 If postoperative RT RT field includes tumor bed X
 If postoperative RT RT field includes tumor bed Y
 If postoperative RT RT field includes regional LNs area X
 If postoperative RT RT field includes regional LNs area Y
 Beam shaping device

——>>>High tech

Cast was used
 Metal marker was used
 Respiratory synchronization
 Rx planing
 Conformal therapy2
 High technology
 Shell was used

——>>>Hdr1

HDR given
 Primary tumor response after external beam HDR
 Optimization1 HDR
 Optimization2 HDR
 Optimization3 HDR
 Optimization4 HDR
 Optimization5 HDR
 Optimization6 HDR
 Treatment planning in each session1 HDR
 Treatment planning in each session2 HDR
 Treatment planning in each session3 HDR
 Treatment planning in each session4 HDR
 Treatment planning in each session5 HDR
 Treatment planning in each session6 HDR
 Multiple reference point1 HDR
 Multiple reference point2 HDR
 Multiple reference point3 HDR
 Multiple reference point4 HDR
 Multiple reference point5 HDR
 Multiple reference point6 HDR
 HDR dose1
 Reference point1 HDR
 Reference point2 HDR
 Reference point3 HDR
 Reference point4 HDR
 Reference point5 HDR
 Reference point6 HDR
 Type of applicator1 HDR
 Type of applicator2 HDR
 Type of applicator3 HDR
 Type of applicator4 HDR
 Type of applicator5 HDR
 Type of applicator6 HDR
 irradiated area X1 HDR
 Date1 HDR
 Type of applicator11 HDR
 Type of applicator12 HDR

Date4 HDR
 Date5 HDR
 Date6 HDR
 HDR dose2
 irradiated area X6 HDR
 irradiated area X5 HDR
 irradiated area X4 HDR
 irradiated area X3 HDR
 irradiated area X2 HDR
 irradiated area Y1 HDR
 irradiated area Y2 HDR
 irradiated area Y3 HDR
 irradiated area Y4 HDR
 irradiated area Y5 HDR
 irradiated area Y6 HDR
 irradiated area Z1 HDR
 irradiated area Z2 HDR
 irradiated area Z3 HDR
 irradiated area Z4 HDR
 irradiated area Z5 HDR
 irradiated area Z6 HDR
 HDR dose3
 HDR dose4
 HDR dose5
 HDR dose6
 Mucosal surface dose1 HDR
 Mucosal surface dose2 HDR
 Mucosal surface dose3 HDR
 Mucosal surface dose4 HDR
 Mucosal surface dose5 HDR
 Mucosal surface dose6 HDR
 Radionuclide

 ----->>>Hdr2
 Optimization7 HDR
 Optimization8 HDR
 Optimization9 HDR
 Optimization10 HDR
 Optimization11 HDR
 Optimization12 HDR
 Treatment planning in each session7 HDR
 Treatment planning in each session8 HDR
 Treatment planning in each session9 HDR
 Treatment planning in each session10 HDR
 Treatment planning in each session11 HDR
 Treatment planning in each session12 HDR
 Multiple reference point7 HDR
 Multiple reference point8 HDR
 Multiple reference point9 HDR
 Multiple reference point10 HDR
 Multiple reference point11 HDR
 Multiple reference point12 HDR
 Reference point7 HDR
 Reference point8 HDR
 Reference point9 HDR
 Reference point10 HDR
 Reference point11 HDR
 Reference point12 HDR
 Type of applicator7 HDR
 Type of applicator8 HDR
 Type of applicator9 HDR
 Type of applicator10 HDR
 Reference point4 LDR
 Reference point5 LDR
 Reference point6 LDR

Date7 HDR
 Date8 HDR
 Date9 HDR
 Date10 HDR
 Date11 HDR
 Date12 HDR
 Total HDR dose
 irradiated area X12 HDR
 irradiated area X11 HDR
 irradiated area X10 HDR
 irradiated area X9 HDR
 irradiated area X8 HDR
 irradiated area X7 HDR
 irradiated area Y7 HDR
 irradiated area Y8 HDR
 irradiated area Y9 HDR
 irradiated area Y10 HDR
 irradiated area Y11 HDR
 irradiated area Y12 HDR
 irradiated area Z7 HDR
 irradiated area Z8 HDR
 irradiated area Z9 HDR
 irradiated area Z10 HDR
 irradiated area Z11 HDR
 irradiated area Z12 HDR
 HDR dose7
 HDR dose8
 HDR dose9
 HDR dose10
 HDR dose11
 HDR dose12
 Mucosal surface dose7 HDR
 Mucosal surface dose8 HDR
 Mucosal surface dose9 HDR
 Mucosal surface dose10 HDR
 Mucosal surface dose11 HDR
 Mucosal surface dose12 HDR

 ----->>>Ldr
 LDR given
 Primary tumor response after external beam LDR
 Optimization1 LDR
 Optimization2 LDR
 Optimization3 LDR
 Optimization4 LDR
 Optimization5 LDR
 Optimization6 LDR
 Treatment planning in each session1 LDR
 Treatment planning in each session2 LDR
 Treatment planning in each session3 LDR
 Treatment planning in each session4 LDR
 Treatment planning in each session5 LDR
 Treatment planning in each session6 LDR
 Multiple reference point1 LDR
 Multiple reference point2 LDR
 Multiple reference point3 LDR
 Multiple reference point4 LDR
 Multiple reference point5 LDR
 Multiple reference point6 LDR
 Reference point1 LDR
 Reference point2 LDR
 Reference point3 LDR
 Surgical of metastatic lymph node site Thorax 108
 Surgical of metastatic lymph node site Thorax 109
 Surgical of metastatic lymph node site Thorax 110

Type of applicator1 LDR
 Type of applicator2 LDR
 Type of applicator3 LDR
 Type of applicator4 LDR
 Type of applicator5 LDR
 Type of applicator6 LDR
 Date1 LDR
 Date2 LDR
 Date3 LDR
 Date4 LDR
 Date5 LDR
 Date6 LDR
 LDR dose1
 LDR dose2
 LDR dose3
 LDR dose4
 LDR dose5
 LDR dose6
 irradiated area X1 LDR
 irradiated area X2 LDR
 irradiated area X3 LDR
 irradiated area X4 LDR
 irradiated area X5 LDR
 irradiated area X6 LDR
 irradiated area Y1 LDR
 irradiated area Y2 LDR
 irradiated area Y3 LDR
 irradiated area Y4 LDR
 irradiated area Y5 LDR
 irradiated area Y6 LDR
 Total LDR dose
 irradiated area Z1 LDR
 irradiated area Z2 LDR
 irradiated area Z3 LDR
 irradiated area Z4 LDR
 irradiated area Z5 LDR
 irradiated area Z6 LDR
 Mucosal surface dose1 LDR
 Mucosal surface dose2 LDR
 Mucosal surface dose3 LDR
 Mucosal surface dose4 LDR
 Mucosal surface dose5 LDR
 Mucosal surface dose6 LDR
 Radionuclide

——>>>Surgery1

Esophagectomy performed
 Residual tumor primary a o lymph node R
 Surgical Surgical margin1
 Surgical Surgical margin2
 Surgical Surgical margin3
 Surgical Lymph node dissection D
 Surgical Intramural metastasis
 Surgical of metastatic lymph node site Cervix 100
 Surgical of metastatic lymph node site Cervix 101
 Surgical of metastatic lymph node site Cervix 102
 Surgical of metastatic lymph node site Cervix 103
 Surgical of metastatic lymph node site Cervix 104
 Surgical of metastatic lymph node site Thorax 105
 Surgical of metastatic lymph node site Thorax 106
 Surgical of metastatic lymph node site Thorax 107
 Path of metastatic lymph node site Thorax 112
 Path of metastatic lymph node site Abdomen 8
 Path of metastatic lymph node site Abdomen 9
 Path of metastatic lymph node site Abdomen 16

Surgical of metastatic lymph node site Thorax 111
 Surgical of metastatic lymph node site Thorax 112
 Surgical of metastatic lymph node site Abdomen 1
 Surgical of metastatic lymph node site Abdomen 2
 Surgical of metastatic lymph node site Abdomen 3
 Surgical of metastatic lymph node site Abdomen 4
 Surgical of metastatic lymph node site Abdomen 5
 Surgical of metastatic lymph node site Abdomen 6
 Surgical of metastatic lymph node site Abdomen 7
 Surgical of metastatic lymph node site Abdomen 8
 Surgical of metastatic lymph node site Abdomen 9
 Surgical of metastatic lymph node site Abdomen 16
 Surgical Surgical T factor
 Surgical Surgical N factor1
 Surgical Surgical N factor2
 Surgical Surgical N factor3
 Surgical Stage1
 Surgical Stage2
 Surgical Curability
 Reconstruction route
 Reconstruction organ used
 If combined resection specify 1
 If combined resection specify 2
 If combined resection specify 3
 Gastric invasion
 Cervical invasion
 Date of esophagectomy
 Surgical Noof clinically metastatic lymph node
 Surgical Noof resected lymph node
 Surgical of metastatic lymph node site Thorax 106 rec
 Surgical of metastatic lymph node site Thorax 106 pre
 Surgical of metastatic lymph node site Thorax 106 tbR
 Surgical of metastatic lymph node site Thorax 106 tbL
 Surgical of metastatic lymph node site Cervix 102 mid
 Surgical of metastatic lymph node site Cervix 102 up
 Type of Surgery

——>>>Surgery2

Path Surgical margin1
 Path Surgical margin2
 Path Surgical margin3
 Path Intramural metastasis
 Path of metastatic lymph node site Cervix 100
 Path of metastatic lymph node site Thorax 105
 Path of metastatic lymph node site Abdomen 1
 Path of metastatic lymph node site Cervix 101
 Path of metastatic lymph node site Thorax 106
 Path of metastatic lymph node site Abdomen 2
 Path of metastatic lymph node site Cervix 102
 Path of metastatic lymph node site Thorax 107
 Path of metastatic lymph node site Abdomen 3
 Path of metastatic lymph node site Cervix 103
 Path of metastatic lymph node site Thorax 108
 Path of metastatic lymph node site Abdomen 4
 Path of metastatic lymph node site Cervix 104
 Path of metastatic lymph node site Thorax 109
 Path of metastatic lymph node site Abdomen 5
 Path of metastatic lymph node site Thorax 110
 Path of metastatic lymph node site Abdomen 6
 Path of metastatic lymph node site Thorax 111
 Path of metastatic lymph node site Abdomen 7
 Agents4 Unknown
 Number of cycle Concurrent
 Number of cycle PreRT
 Number of cycle PostRT

Path Surgical T factor
 Path Surgical N factor1
 Path Surgical N factor2
 Path Stage1
 Path Stage2
 Path Curability
 ly
 v
 ie
 Inf
 Skip lesion
 Path Noof pathologically metastatic lymph node
 Path Noof resected lymph node
 Path of metastatic lymph node site Cervix 102 mid
 Path of metastatic lymph node site Cervix 102 up
 Path of metastatic lymph node site Thorax 106 rec
 Path of metastatic lymph node site Thorax 106 pre
 Path of metastatic lymph node site Thorax 106 tbL
 Path of metastatic lymph node site Thorax 106 tbR

————>>>Chemo

Medical oncologist consulted
 Chemotherapy given
 Reason not given
 Total number of cycles
 Therapy given Concurrent
 Therapy given PreRT
 Therapy given PostRT
 Therapy given PreOp
 Therapy given PostOp
 Therapy given Unknown
 Interval of chemo Concurrent
 Interval of chemo PreRT
 Interval of chemo PostRT
 Interval of chemo PreOp
 Interval of chemo PostOp
 Interval of chemo Unknown
 Agents1 Concurrent
 Agents1 PreRT
 Agents2 Concurrent
 Agents2 PreRT
 Agents1 PostRT
 Agents1 PreOp
 Agents1 PostOp
 Agents1 Unknown
 Agents2 PostRT
 Agents2 PreOp
 Agents2 PostOp
 Agents2 Unknown
 Agents3 Concurrent
 Agents3 PreRT
 Agents3 PostRT
 Agents3 PreOp
 Agents3 PostOp
 Agents3 Unknown
 Agents4 Concurrent
 Agents4 PreRT
 Agents4 PostRT
 Agents4 PreOp
 Agents4 PostOp
 Grade Comp late 1
 Dilatation after RT 1
 Site Comp late 2
 Grade Comp late 2
 Dilatation after RT 2

Number of cycle PreOp
 Number of cycle PostOp
 Number of cycle Unknown

————>>>Outcome

Last visit
 New primary cancer YN
 Patient status
 Stent used
 Gasterostomy
 Cause of death
 NG tube
 Parenteral nutritional support
 Other nutritional support
 Karnofsky performance status
 Swallowing function Outcome
 New primary cancer spcify
 Date of death

————>>>Relapse

Did patient experience a recurrence
 Site First failure
 Detection method1 First failure
 Detection method2 First failure
 Detection method3 First failure
 If metastasis Y specify 1
 Site Second failure
 Detection method1 Second failure
 Detection method2 Second failure
 Detection method3 Second failure
 If metastasis Y specify 2
 Date Second failure
 Date First failure
 Site Regrowth
 Detection method1 Regrowth
 Detection method2 Regrowth
 Detection method3 Regrowth
 Date Regrowth

————>>>Complication1

If the site is esophagus specify
 Did patient experience acute complication
 Site Comp acute 1
 Grade Comp acute 1
 Site Comp acute 2
 Grade Comp acute 2
 Site Comp acute 3
 Grade Comp acute 3
 Site Comp acute 4
 Grade Comp acute 4
 Date Comp acute2
 Date Comp acute1
 Date Comp acute3
 Date Comp acute4

————>>>Complication2

If the site is esophagu ,specify
 Date Comp late1
 Did patient experience late complication
 Site Comp late 1

Site Comp late 3
Grade Comp late 3
Dilatation after RT 3
Site Comp late 4
Grade Comp late 4
Dilatation after RT 4
Date Comp late2
Date Comp late3
Date Comp late4

——>>>Comment
Comments

——>>>Menu

Surveyor
Total number in database
record
help

——>>>Eligibility

ID
NO
Date Input
Institution
Chart ID Hospital
Treated from 1999 to 2001
Distant metastasis
Stage
Prior malignancesd
Karnofsky performance status Elig
Chart ID(RT department)
Case Eligible

——>>>Demographics

RT department
Other department
In patient department
Imaging
Zip code
Date of birth Demographics
Gender

——>>>Symptom

Cough
Hemosputum
Dyspnea
Hoarseness
Chest pain
Fever
Neoplastic syndrome
Other

——>>>History

Interstitial pneumonitis or fibrosis
Pulmonary tuberculosis
Asthma/chronic bronchitis
Pulmonary emphysema
Cardiovascular disease
Diabetes
HCV/HB(+)
Chronic nephritis/ renal failure
Pollution(KOGAI NINTEI)
Occupational exposure
Karnofsky performance status
piece
years
Height cm
Weight kg
Respiratory function PaO2 mmHg
Respiratory function PaCo2 mmHg
Respiratory function DLCO
Respiratory function FEV10
Respiratory function VC
Body weight loss
Tumor marker CEA ng ml
Tumor marker NSE ng ml
ProGRP(ng/ml)
First failure Site

Tumor marker SCC ng ml
Cyfra(ng/ml)
Lost weight
Tumor marker SLX ng ml

——>>>Workup1

Chest Xp
Obstructive pneumonitis(atelectasis)
CT scan
Distal extent of lymph node metastasis
MRI
Distal extent of lymph node metastasis MRI
Bronchoscopy
Chest Xp Maximum diameter of primary tumor cm
CT scan Maximum diameter of primary tumor cm
CT scan Maximum diameter of lymph node metastasis cm
MRI Maximum diameter of primary tumor cm
MRI Maximum diameter of lymph node metastasis cm
CT brain
MR brain
CT abdomen
US abdomen
Bone scinti
PET
Mediastinoscopy

——>>>Workup2

Location of primary tumor1
Location of primary tumor2
Location of primary tumor3
Segment of primary tumor1
Segment of primary tumor2
Sperior sulcus tumor
T primary tumor
Clinical staging UICC 97 N Regional lymph nodes
Clinical staging Stage1
More than 3 cm in greatest dimension
Involves the main bronchus, 2 cm or more distal to the carina
Invades the visceral pleura
Associated with atelectasis or obstructive pneumonitis
1 Chest wall including superior sulcus tumors
2 Diaphragm
3 Mediastinal pleura
4 Parietal pericardium
Tumor in the main bronchus less than 2 cm
Associated atelectasis or obstructive pneumonitis
1 mediastinum
2 heart
3 great vessels
4 trachea
5 esophagus
6 vertebral body
7 carina
Separate tumor nodules in the same lobe
Tumor with a malignant pleural effusion
Metastasis to ipsilateral mediastinal
Metastasis to subcarinal lymph node(s)
Metastasis to contralateral mediastinal
Metastasis to contralateral hilar
Metastasis to ipsilateral scaleneor supraclavicular
Metastasis to contralateral scalene or supraclavicular

——>>>Relapse

Did patient experience a failure?
Start_date_ext_beam

Detection method1 First failure
 Detection method2 First failure
 Detection method3 First failure
 Second failure Site
 Detection method1 Second failure
 Detection method2 Second failure
 Detection method3 Second failure
 Regrowth Site
 Detection method1 Regrowth
 Detection method2 Regrowth
 Detection method3 Regrowth
 Date Relapse First failure
 Date Relapse Second failure
 Date Relapse Regrowth

——>>>Rxcourse

Investigational protocol
 Planned External beam
 Planned Split course
 Planned Brachytherapy
 Planned Surgical resection
 Planned Chemotherapy
 Given External beam
 Given Split course
 Given Brachytherapy
 Given Chemotherapy
 Reason incomplete
 Admission for initial treatment
 Given Surgical resection
 Protocol
 Planned Total dose cGy
 Planned Total fractions
 Given Total fractions
 Given Total dose cGy
 Planned Dose fx cGy
 Planned Dose fx cGy 2
 Given Dose fx cGy
 Given Dose fx cGy 2
 Planned If hyperfraction1
 Planned If hyperfraction2
 Planned If hyperfraction3
 Given If hyperfraction1
 Given If hyperfraction2
 Given If hyperfraction3
 Planned If hyperfractionInterval
 Given If hyperfraction Interval
 Did patient complete planned treatment
 Clinical trial group

——>>>Exb1

Prescription
 High technology_3DCRT_IMRT_SRT_particle_used
 Primary tumor
 Ipsilateral hilus
 Ipsilateral mediastinum
 Contralateral mediastinum
 Contralateral hilus
 Ipsilateral supraclavicular
 Contralateral supraclavicular
 Lower mediastinum
 Stump
 PCI employed
 Treatment planning machine
 D100_PTV
 V100_PTV

Stop_date_ext_beam
 Dose_to_spinal_cord(cGy)
 Supraclavicular_dose(cGy)
 Total_dose
 fraction
 days
 Primary_lesion_GTV_max
 Metastatic_LN_GTV_node_max
 Resional_LN_area_CTV_subclinical_reduced
 Metastatic_LN_GTV_node_reduced
 Resional_LN_area_CTV_subclinical_max
 Ipsilateral_hilum_max

——>>>Extb2

All fields treated each day
 Fields reduced during RT
 Beam type
 Beam type field1
 Beam type field2
 Beam type field3
 Beam type field4
 Max_beam_energy
 Shrinkage_beam_energy_1
 Shrinkage_beam_energy_2
 Shrinkage_beam_energy_3
 Shrinkage_beam_energy_4
 Max_technique
 Technique_1
 Technique_2
 Technique_3
 Technique_4
 Maximum_radiation_field_x
 Maximum_radiation_field_y
 Max_area
 Dose(cGy)
 X field1
 Y field1
 Area field1
 X field2
 Y field2
 Area field2
 X field3
 Y field3
 Area field3
 X field4
 Y field4
 Area field4
 Dose(cGy) field1
 Dose(cGy) field2
 Dose(cGy) field3
 Dose(cGy) field4

——>>>High tech

Cast was used
 Shell was used
 Respiratory Synchronization
 Metal marker was used
 Conformal therapy1
 Conformal therapy2
 Beam shaping device
 Patient bolus used?
 Rx planning
 D95_PTV
 Optimization4
 Optimization5

Mean Dose PTV
 Maximum Dose PTV
 D95 CTV
 D100 CTV
 V100 CTV
 Mean Dose CTV
 Maximum Dose CTV
 Organ Mean Dose PTV
 Organ Maximum Dose PTV
 Organ Minimum Dose PTV
 Organ Mean Dose CTV
 Organ Maximum Dose CTV
 Organ Minimum Dose CTV
 Organ at risk
 Referencepoint CTV
 Reference point PTV
 Dose CTV
 Dose PTV

 ——>>>Hdr
 HDR given
 Type of sources HDR
 Type of applicator1
 Type of applicator2
 Type of applicator3
 Type of applicator4
 Type of applicator5
 Type of applicator6
 Type of applicator7
 Type of applicator8
 Type of applicator9
 Type of applicator10
 Type of applicator11
 Type of applicator12
 Date1
 Date2
 Date3
 Date4
 Date5
 Date6
 Date7
 Date8
 Date9
 Date10
 Date11
 Date12
 HDR dose 1
 HDR dose 2
 HDR dose 3
 HDR dose 4
 HDR dose 5
 HDR dose 6
 HDR dose 7
 HDR dose 8
 HDR dose 9
 HDR dose 10
 HDR dose 11
 HDR dose 12
 Total HDR dose
 Optimization1
 Optimization2
 Optimization3
 Multiple reference point8
 Multiple reference point9
 Multiple reference point10

Optimization6
 Optimization7
 Optimization8
 Optimization9
 Optimization10
 Optimization11
 Optimization12
 Treatment planning1
 Treatment planning2
 Treatment planning3
 Treatment planning4
 Treatment planning5
 Treatment planning6
 Treatment planning7
 Treatment planning8
 Treatment planning9
 Treatment planning10
 Treatment planning11
 Treatment planning12
 Irradiated areaX1
 Irradiated areaX2
 Irradiated areaX3
 Irradiated areaX4
 Irradiated areaX5
 Irradiated areaX6
 Irradiated areaX7
 Irradiated areaX8
 Irradiated areaX9
 Irradiated areaX10
 Irradiated areaX11
 Irradiated areaX12
 Irradiated areaY1
 Irradiated areaY2
 Irradiated areaY3
 Irradiated areaY4
 Irradiated areaY5
 Irradiated areaY6
 Irradiated areaY7
 Irradiated areaY8
 Irradiated areaY9
 Irradiated areaY10
 Irradiated areaY11
 Irradiated areaY12
 Irradiated areaZ1
 Irradiated areaZ2
 Irradiated areaZ3
 Irradiated areaZ4
 Irradiated areaZ5
 Irradiated areaZ6
 Irradiated areaZ7
 Irradiated areaZ8
 Irradiated areaZ9
 Irradiated areaZ10
 Irradiated areaZ11
 Irradiated areaZ12
 Multiple reference point1
 Multiple reference point2
 Multiple reference point3
 Multiple reference point4
 Multiple reference point5
 Multiple reference point6
 Multiple reference point7
 Br
 PA
 PV